long term side effects of glp 1 drugs Do The Benefits GLP-1 OutWeigh the Negatives? Press Release Page | Press

doi: 10.1186/1742-2094-5-19

April 2024 - On April 9, 2024, the defendants Novo Nordisk and Eli Lilly filed a position statement where they tried to classify lawsuits into different groups

Injectable WEGOVY achieves up to 1517% weight loss on average, and ZEPBOUND has demonstrated up to 22.5% weight loss at the highest doses

It has demonstrated significant weight loss, achieving a reduction of up to 24.2%

Whereas the North American population appears to prefer single-use auto-injectors, in Europe there is a preference for multi-use disposable pen injectors

Your attorney writes and files a legal complaint against Ozempics manufacturer, Novo Nordisk